{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:54:28Z","timestamp":1784868868126,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The albumin\u2013bilirubin (ALBI) score is calculated using only serum albumin and bilirubin levels, and was developed as a simple method to assess hepatic function. In this study, a total of 409 patients with primary biliary cholangitis (PBC) were enrolled between March 1990 and October 2018. The predictive performances of the ALBI score and other well-established prognostic scores were compared using time-dependent receiver operating characteristic (ROC) analysis. During the follow-up period, 60 patients died, 45 due to liver-related diseases and 15 due to non-liver-related diseases, and 16 patients underwent liver transplantation. Time-dependent ROC analysis showed that the ALBI score has higher the areas under the ROC curves (AUROCs) than the Child\u2013Pugh (C\u2013P) score at each time point; AUROCs at 3, 5, and 10\u00a0years after the start of follow-up were 0.94, 0.91, and 0.90 for the ALBI score, and 0.89, 0.88, and 0.82 for the C\u2013P score, respectively. The ALBI score showed the highest AUROCs within 2\u00a0years after the start of observation; beyond 2\u00a0years, however, the Mayo score had better prognostic ability for mortality and liver transplantation. The ALBI score\/grade, derived from objective blood tests, and the Mayo score were superior prognostic tools in PBC patients.<\/jats:p>","DOI":"10.1038\/s41598-020-74732-3","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:03:16Z","timestamp":1603188196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The albumin\u2013bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC"],"prefix":"10.1038","volume":"10","author":[{"given":"Takanori","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Morooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"74732_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C. & Mayo, M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 69, 394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145 (2019).","journal-title":"Hepatology"},{"key":"74732_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","volume":"377","author":"C Selmi","year":"2011","unstructured":"Selmi, C., Bowlus, C. L., Gershwin, M. E. & Coppel, R. L. Primary biliary cirrhosis. Lancet 377, 1600\u20131609. https:\/\/doi.org\/10.1016\/S0140-6736(10)61965-4 (2011).","journal-title":"Lancet"},{"key":"74732_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/hep.26322","volume":"58","author":"LN Zhang","year":"2013","unstructured":"Zhang, L. N. et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 58, 264\u2013272. https:\/\/doi.org\/10.1002\/hep.26322 (2013).","journal-title":"Hepatology"},{"key":"74732_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares, A., Caballeria, L. & Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130, 715\u2013720. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029 (2006).","journal-title":"Gastroenterology"},{"key":"74732_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath, P. S. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464\u2013470. https:\/\/doi.org\/10.1053\/jhep.2001.22172 (2001).","journal-title":"Hepatology"},{"key":"74732_CR6","first-page":"732","volume":"44","author":"GM van Dam","year":"1997","unstructured":"van Dam, G. M. et al. Primary biliary cirrhosis: Dutch application of the Mayo Model before and after orthotopic liver transplantation. Hepatogastroenterology 44, 732\u2013743 (1997).","journal-title":"Hepatogastroenterology"},{"key":"74732_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince, M., Chetwynd, A., Newman, W., Metcalf, J. V. & James, O. F. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123, 1044\u20131051. https:\/\/doi.org\/10.1053\/gast.2002.36027 (2002).","journal-title":"Gastroenterology"},{"key":"74732_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0270-9139(94)90144-9","volume":"20","author":"PA Murtaugh","year":"1994","unstructured":"Murtaugh, P. A. et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 20, 126\u2013134. https:\/\/doi.org\/10.1016\/0270-9139(94)90144-9 (1994).","journal-title":"Hepatology"},{"key":"74732_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646\u2013649. https:\/\/doi.org\/10.1002\/bjs.1800600817 (1973).","journal-title":"Br. J. Surg."},{"key":"74732_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33, 550\u2013558. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151 (2015).","journal-title":"J. Clin. Oncol."},{"key":"74732_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","volume":"34\u201335","author":"JC Goet","year":"2018","unstructured":"Goet, J. C., Harms, M. H., Carbone, M. & Hansen, B. E. Risk stratification and prognostic modelling in primary biliary cholangitis. Best Pract. Res. Clin. Gastroenterol. 34\u201335, 95\u2013106. https:\/\/doi.org\/10.1016\/j.bpg.2018.06.006 (2018).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"74732_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178 (2006).","journal-title":"Hepatology"},{"key":"74732_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","volume":"61","author":"PJ Heagerty","year":"2005","unstructured":"Heagerty, P. J. & Zheng, Y. Survival model predictive accuracy and ROC curves. Biometrics 61, 92\u2013105. https:\/\/doi.org\/10.1111\/j.0006-341X.2005.030814.x (2005).","journal-title":"Biometrics"},{"key":"74732_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341x.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337\u2013344. https:\/\/doi.org\/10.1111\/j.0006-341x.2000.00337.x (2000).","journal-title":"Biometrics"},{"key":"74732_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913 (2018).","journal-title":"Hepatology"},{"key":"74732_CR16","doi-asserted-by":"publisher","unstructured":"Working Subgroup for Clinical Practice Guidelines for Primary Biliary, C. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res44 Suppl S1, 71\u201390. https:\/\/doi.org\/10.1111\/hepr.12270 (2014).","DOI":"10.1111\/hepr.12270"},{"key":"74732_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1159\/000480256","volume":"35","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka, A. et al. Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig. Dis. 35, 602\u2013610. https:\/\/doi.org\/10.1159\/000480256 (2017).","journal-title":"Dig. Dis."},{"key":"74732_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000494844","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka, A., Kumada, T., Michitaka, K. & Kudo, M. Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer 8, 312\u2013325. https:\/\/doi.org\/10.1159\/000494844 (2019).","journal-title":"Liver Cancer"},{"key":"74732_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/liv.14249","volume":"40","author":"SY Ho","year":"2020","unstructured":"Ho, S. Y. et al. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver Int. 40, 205\u2013214. https:\/\/doi.org\/10.1111\/liv.14249 (2020).","journal-title":"Liver Int."},{"key":"74732_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081258","author":"K Fujita","year":"2019","unstructured":"Fujita, K. et al. Prediction of transplant-free survival through albumin\u2013bilirubin score in primary biliary cholangitis. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm8081258 (2019).","journal-title":"J. Clin. Med."},{"key":"74732_CR21","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/jgh.12938","volume":"30","author":"AW Chan","year":"2015","unstructured":"Chan, A. W. et al. New simple prognostic score for primary biliary cirrhosis: albumin\u2013bilirubin score. J. Gastroenterol. Hepatol. 30, 1391\u20131396. https:\/\/doi.org\/10.1111\/jgh.12938 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"74732_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1053\/jlts.2000.6503","volume":"6","author":"WR Kim","year":"2000","unstructured":"Kim, W. R. et al. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl 6, 489\u2013494. https:\/\/doi.org\/10.1053\/jlts.2000.6503 (2000).","journal-title":"Liver Transpl"},{"key":"74732_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/apt.15533","volume":"50","author":"CF Murillo Perez","year":"2019","unstructured":"Murillo Perez, C. F. et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol. Ther. 50, 1127\u20131136. https:\/\/doi.org\/10.1111\/apt.15533 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"key":"74732_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14929","author":"S Joshita","year":"2019","unstructured":"Joshita, S. et al. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.14929 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"74732_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.28017","volume":"63","author":"M Carbone","year":"2016","unstructured":"Carbone, M. et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 63, 930\u2013950. https:\/\/doi.org\/10.1002\/hep.28017 (2016).","journal-title":"Hepatology"},{"key":"74732_CR26","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers, W. J. et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149, 1804\u20131812. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.061 (2015).","journal-title":"Gastroenterology"},{"key":"74732_CR27","first-page":"1257","volume":"60","author":"P Scheuer","year":"1967","unstructured":"Scheuer, P. Primary biliary cirrhosis. Proc. R. Soc. Med. 60, 1257\u20131260 (1967).","journal-title":"Proc. R. Soc. Med."},{"key":"74732_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693\u2013699. https:\/\/doi.org\/10.1056\/NEJM199603143341104 (1996).","journal-title":"N. Engl. J. Med."},{"key":"74732_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3760\/cma.j.issn.1007-3418.2017.11.004","volume":"25","author":"Y Han","year":"2017","unstructured":"Han, Y. & Chen, Y. An interpretation of 2017 EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. Zhonghua Gan Zang Bing Za Zhi 25, 814\u2013818. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2017.11.004 (2017).","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"74732_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouilleres","year":"1998","unstructured":"Chazouilleres, O. et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28, 296\u2013301. https:\/\/doi.org\/10.1002\/hep.510280203 (1998).","journal-title":"Hepatology"},{"key":"74732_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74732-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:55:28Z","timestamp":1670363728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74732-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74732"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74732-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17812"}}